CA3101041A1 - Structurally modified fatty acids for improving glycemic control and treating inflammatory bowel disease - Google Patents

Structurally modified fatty acids for improving glycemic control and treating inflammatory bowel disease Download PDF

Info

Publication number
CA3101041A1
CA3101041A1 CA3101041A CA3101041A CA3101041A1 CA 3101041 A1 CA3101041 A1 CA 3101041A1 CA 3101041 A CA3101041 A CA 3101041A CA 3101041 A CA3101041 A CA 3101041A CA 3101041 A1 CA3101041 A1 CA 3101041A1
Authority
CA
Canada
Prior art keywords
group
compound
formula
ibd
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3101041A
Other languages
English (en)
French (fr)
Inventor
David Alan Fraser
Tore Skjaeret
Detlef Schuppan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northsea Therapeutics BV
BASF AS
Original Assignee
Northsea Therapeutics BV
BASF AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northsea Therapeutics BV, BASF AS filed Critical Northsea Therapeutics BV
Publication of CA3101041A1 publication Critical patent/CA3101041A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/54—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and unsaturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3101041A 2018-05-23 2019-05-22 Structurally modified fatty acids for improving glycemic control and treating inflammatory bowel disease Pending CA3101041A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NO20180714 2018-05-23
NO20180714 2018-05-23
PCT/IB2019/000655 WO2019224602A2 (en) 2018-05-23 2019-05-22 Structurally modified fatty acids for improving glycemic control and treating inflammatory bowel disease

Publications (1)

Publication Number Publication Date
CA3101041A1 true CA3101041A1 (en) 2019-11-28

Family

ID=67688797

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3101041A Pending CA3101041A1 (en) 2018-05-23 2019-05-22 Structurally modified fatty acids for improving glycemic control and treating inflammatory bowel disease

Country Status (8)

Country Link
US (2) US20210290576A1 (https=)
EP (1) EP3796901A2 (https=)
JP (1) JP7508447B2 (https=)
KR (2) KR20210015883A (https=)
CN (1) CN112351775A (https=)
AU (1) AU2019274203B2 (https=)
CA (1) CA3101041A1 (https=)
WO (1) WO2019224602A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102760537B1 (ko) 2022-01-20 2025-02-03 한국과학기술연구원 삼원계 광활성층 조성물 및 이를 포함하는 유기태양전지

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009061208A1 (en) 2007-11-09 2009-05-14 Pronova Biopharma Norge As Lipid compounds for use in cosmetic products, as food supplement or as a medicament
EP2147910A1 (en) * 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
BRPI1015120B8 (pt) * 2009-05-08 2022-02-15 Basf As Composto lipídico alfa-substituídos, derivados de ácidos graxos beta-oxo poli-insaturados, composição farmacêutica e lipídica e métodos para produzir composto lipídico e ácido 2-((5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaeniloxi)butanóico
EP2526084A1 (en) 2010-01-20 2012-11-28 Pronova BioPharma Norge AS Salicylate fatty acid derivatives
CN102946875A (zh) * 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
PL2961727T3 (pl) 2013-02-28 2017-06-30 Pronova Biopharma Norge As Sposób wytwarzania kwasu 2-((5Z,8Z, 11Z,14Z,17Z)-ejkoza-5,8,11,14,17-pentaenyloksy)butanowego
KR20180010181A (ko) 2015-04-01 2018-01-30 프로노바 바이오파마 너지 에이에스 Apo c3 의 저하를 위한 티아 옥소 화합물의 용도
ES2980790T3 (es) * 2015-04-28 2024-10-03 Basf As Acidos grasos estructuralmente mejorados que contienen azufre para su uso en el tratamiento de la esteatohepatitis no alcohólica

Also Published As

Publication number Publication date
JP2021526552A (ja) 2021-10-07
JP7508447B2 (ja) 2024-07-01
US20210290576A1 (en) 2021-09-23
AU2019274203A1 (en) 2021-01-07
EP3796901A2 (en) 2021-03-31
KR20250150676A (ko) 2025-10-20
KR20210015883A (ko) 2021-02-10
WO2019224602A3 (en) 2020-03-05
US20260000632A1 (en) 2026-01-01
CN112351775A (zh) 2021-02-09
AU2019274203B2 (en) 2025-01-02
WO2019224602A2 (en) 2019-11-28

Similar Documents

Publication Publication Date Title
JP6986022B2 (ja) Ｆｘｒアゴニストを使用するための方法
JP6941109B2 (ja) Ｆｘｒアゴニストを使用するための方法
TWI814744B (zh) 包含acc抑制劑之組合療法
JP4938905B2 (ja) 選択的ｓ１ｐ１レセプターアゴニストの投与法
JP7053478B2 (ja) Ｆｘｒアゴニストを使用するための方法
US10208080B2 (en) Methods of treating and/or preventing affective disorders of the nervous system (depression) using aminosterols
US20220000824A1 (en) Treatment of pulmonary arterial hypertension using therapeutically effective oral doses of 10-nitro-9(e)-octadec-9-enoic acid
JP2019142925A (ja) 糖尿病の治療用組成物および方法
US20260000632A1 (en) Structurally modified fatty acids for improving glycemic control and treating inflammatory bowel disease
JP2011502112A (ja) 抗ガン治療の副作用を治療するための新規組成物
CN106573063A (zh) 用于治疗糖尿病的咖啡醇
US20240325336A1 (en) Combination therapies comprising oxygen-containing structurally enhanced fatty acids for treatment of non-alcoholic steatohepatitis
US20150224081A1 (en) Composition and method for treatment of diabetes
CN119730845A (zh) 用于改善视网膜/认知功能和动脉粥样硬化的极长链多不饱和脂肪酸（vlcpufa）

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220920

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241218

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250422

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250509

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250513

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250513